General Info

Repligen Corporation develops novel therapeutics for the treatment of diseases of the central nervous and immune systems. It provides clinical development programs for the areas of schizophrenia, obsessive-compulsive disorder, bipolar disorder, multiple sclerosis and lupus. Repligen markets two niche products, Protein A and SecreFlo. Protein A is a consumable reagent used by the pharmaceutical industry to manufacture a class of drugs called monoclonal antibodies. The company offers a number of products based on recombinant Protein A, which include recombinant Protein A, Immobilized Protein A and Protein A ELISA Kits. SecreFlo is approved by the Food and Drug Administration to aid in the diagnosis of pancreatic exocrine dysfunction and gastrinoma and to aid in the identification and cannulation of the pancreatic ducts in patients undergoing endoscopic retrograde cholangiopancreatography. Repligen Corporation was established in 1981 and is headquartered in Waltham, Mass.